SCHEMBL5656913

SCHEMBL5656913

OCc1ccccc1Oc1cccc2c1CCCC2

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RXRA P19793 9/20 0.44
RXRB P28702 9/20 0.44
RXRG P48443 6/20 0.44
BCL2L1 Q07817 1/20 0.43
BAD Q92934 1/20 0.43
MCL1 Q07820 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
IDO1 P14902 2/20 0.39
CHRNE Q04844 1/20 0.38
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658539 0.84 LMNA (0.42) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL31312989 0.83 BCL2L1 (0.54) SMN1; SMN2RXRARXRBRXRGBCL2L1
SCHEMBL5659543 0.82 RXRB (0.59) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL5660017 0.81 SMN1; SMN2 (0.40) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL8872355 0.79 BCL2L1 (0.55) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL5753897 0.78 BCL2L1 (0.53) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL5950358 0.77 SLC6A2 (0.50) KDM4E
SCHEMBL19354043 0.76 BCL2L1 (0.50) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL30620247 0.76 BCL2L1 (0.50) LMNASMN1; SMN2RXRARXRBRXRG
SCHEMBL5657571 0.75 RXRA (0.53) RXRARXRBRXRGMCL1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262309-B2 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) 2007-08-28 US disclosed
EP-1492795-B1 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF PLIVA ISTRAZIVACKI INST D O O (HR) 2005-11-16 EP disclosed
US-20050137249-A1 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) 2005-06-23 US disclosed
US-20050130964-A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-06-16 US disclosed
EP-1492795-A1 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2005-01-05 EP disclosed
WO-2003084961-A1 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130964-A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof TNF, IL1A, IL1B LMNA 3718/4885SMN1; SMN2 3760/4885RXRA 3077/4885
US-20050137249-A1 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof TNF, IL1A, IL1B LMNA 2813/4885SMN1; SMN2 3809/4885RXRA 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.